![Psychedelic therapy: Psilocybin shows promise as depression treatment in largest trial yet | New Scientist Psychedelic therapy: Psilocybin shows promise as depression treatment in largest trial yet | New Scientist](https://images.newscientist.com/wp-content/uploads/2021/11/10154115/PRI_209558802.jpg?width=300)
Psychedelic therapy: Psilocybin shows promise as depression treatment in largest trial yet | New Scientist
![Hallucinogen in 'magic mushrooms' relieves depression in largest clinical trial to date | Live Science Hallucinogen in 'magic mushrooms' relieves depression in largest clinical trial to date | Live Science](https://cdn.mos.cms.futurecdn.net/XDf6rafLdyBcaqgnvJPnpb.jpg)
Hallucinogen in 'magic mushrooms' relieves depression in largest clinical trial to date | Live Science
![Psilocybin Found to Rapidly Improve Depressive Symptoms in Clinical Trial | Columbia University Department of Psychiatry Psilocybin Found to Rapidly Improve Depressive Symptoms in Clinical Trial | Columbia University Department of Psychiatry](https://www.columbiapsychiatry.org/sites/default/files/styles/cola_media_1280_16_9/public/media/images/2021-11/gettyimages-1276620416.jpg?itok=lXVd9E6D)
Psilocybin Found to Rapidly Improve Depressive Symptoms in Clinical Trial | Columbia University Department of Psychiatry
Braxia Scientific Corp. hits milestone as landmark psilocybin clinical trial begins with participants receiving first doses
![Magic mushroom compound performs as well as antidepressant in small study | Imperial News | Imperial College London Magic mushroom compound performs as well as antidepressant in small study | Imperial News | Imperial College London](https://www.imperial.ac.uk/ImageCropToolT4/imageTool/uploaded-images/190822-psilodep-psychedelic-research-006_1618330592369_x2.jpg?r=9992)
Magic mushroom compound performs as well as antidepressant in small study | Imperial News | Imperial College London
![Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder | Business Wire Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder | Business Wire](https://mms.businesswire.com/media/20210518005402/en/1084589/23/Cybin_Primary_Logo_Blue_Final.jpg)